Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
770.610.33%
QQQ
718.350.09%
BTC/USD
79562.222.1087%
DIA
534.380.47%
GLD
407.060.77%
TLT
82.410.41%

Legend Biotech Corp

LEGNNASDAQ
Trade with Public
Trade with Public
$21.87
0.120.55%
Last update: Sep 4, 12:16 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Legend Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Legend Biotech (LEGN).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

11Buy
4Hold
Consensus RatingOverweight# Analysts15Avg. Consensus PT$65Upside to Avg. PT+195.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 4, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$65
Aug 12, 2026Morgan StanleyMatthew HarrisonPT RaiseOverweight$48→$49
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
Benzinga Newsdesk

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Avi Kapoor

PRO
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
Benzinga Newsdesk

PRO
Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved